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 INTRODUCTION
 It has been more than 40 years since the colonoscopic surveillance 
program for colorectal cancer (CRC) in patients with long-stand-
ing ulcerative colitis (UC) was introduced ( 1 ). However, many 
uncertainties remain in managing this potentially challenging 
group of patients.
 First, the true magnitude of CRC risk and how this has 
changed over time needs to be confi rmed. In our earlier study, 
we have showed that the incidence of CRC had signifi cantly 
decreased over time between 1971 and 2000 ( 1 ), and similar 
trends were observed in population-based studies from 
Denmark ( 2 ) and Sweden ( 3 ). However, it is unclear whether 
this trend has continued, as many aspects of surveillance 
programs have changed since our last study. For example, there 
has been an increase in use of advanced techniques, notably 
chromoendoscopy ( 4–6 ), and some dysplastic lesions are now 
increasingly being managed endoscopically instead of by colec-
tomy ( 7–10 ).
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 SUPPLEMENTARY MATERIAL is linked to the online version of the paper at  http://www.nature.com/ajg 
 Am J Gastroenterol 2015; 110:1022–1034; doi: 10.1038/ajg.2015.65; published online 31 March 2015 
 1 Infl ammatory Bowel Disease Unit, St Mark’s Hospital ,  London ,  UK ;  2 Tumour Biology, Barts Cancer Institute, Queen Mary University of London ,  London ,  UK ; 
 3 University Hospital of North Tees ,  Teesside ,  UK ;  4 Department of Colorectal Surgery, St Mark’s Hospital ,  London ,  UK ;  5 Department of Pathology, St Mark’s 
Hospital ,  London ,  UK ;  6 Wolfson Unit for Endoscopy, St Mark’s Hospital ,  London ,  UK ;  7 Co-senior authors .  Correspondence:  Chang-Ho Ryan Choi , MBBS, MSc, 
 Department of Infl ammatory Bowel Disease, St Mark’s Hospital ,  London  HA1 3UJ ,  UK . E-mail:  pacoblue@gmail.com 
 Received  5  September  2014 ;  accepted  3  February  2015 
© 2015 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY
1023
IN
F
LA
M
M
AT
O
R
Y
 B
O
W
E
L 
D
IS
E
A
S
E
Cancer Surveillance in Ulcerative Colitis
 Second, there are limited data on the risk of CRC occurring 
between scheduled surveillance procedures (or interval CRC). It is 
important to quantify these risks and assess how this has changed 
over time, as it may allow us to evaluate the effi  cacy of the colono-
scopic surveillance program.
 Th ird, the prevalence of multifocal lesions occurring in UC 
patients is poorly understood. Previous studies reported the occur-
rence of synchronous cancers ( 11,12 ), but little attention has been 
given to solitary cancers that occur with distinct foci of dysplasia 
elsewhere in the colon. It is essential to distinguish between uni-
focal and multifocal neoplasia as it may indicate etiological dif-
ferences in the underlying carcinogenic process, thus requiring 
diff erent management approaches.
 Finally, there are limited data on the natural history and risk 
of progression to CRC from each grade of premalignant change, 
namely sporadic adenoma, indefi nite for dysplasia, low-grade 
dysplasia (LGD) and high-grade dysplasia (HGD). Th is may 
refl ect the diffi  culties in histological grading of dysplasia ( 13,14 ), 
problems in distinguishing between a sporadic adenoma or UC-
associated dysplasia ( 15 ), as well as challenges in the endoscopic 
detection of subtle dysplastic lesions ( 16 ).
 In this study, we report data from the St Mark’s Hospital UC 
surveillance program, one of the largest and longest-running pro-
grams in the world, with the aim of answering these important 
questions.
 METHODS
 Study population
 St Mark’s Hospital is a tertiary referral center based in the United 
Kingdom, and it started colonoscopic surveillance program in 
1971. Patients with endoscopic and histological evidence of UC 
proximal to the splenic fl exure were traditionally off ered annual 
to biannual surveillance colonoscopies from 8 to 10 years aft er 
onset of UC symptoms.
 Segmental random biopsies were taken throughout the colon, 
with multiple targeted biopsies from any suspicious area of mucosa 
at each surveillance colonoscopy. In more recent years (from 2003 
onwards), chromoendoscopy has been gradually implemented 
where pancolonic dye spray was used to highlight abnormal 
mucosa for targeted biopsy.
 Dysplasia management protocol
 In our center, the management of a neoplastic lesion is based on 
its location within or outside of a diseased segment. Lesions aris-
ing proximal to the maximal extent of the colitis are considered 
sporadic and removed endoscopically. Th e management of lesions 
arising within the diseased segment has evolved over time.
 Historically, colectomy was advised when the presence of 
dysplasia was confi rmed and reviewed independently by two 
experienced pathologists. However, in our current policy, resect-
able dysplastic lesions are removed endoscopically and biopsies 
are taken from its surrounding mucosa with additional segmental 
biopsies taken from the colon. If the lesion is resected in full with-
out evidence of further dysplasia elsewhere, the patient is usually 
advised to undergo close endoscopic surveillance, although the 
option of surgery is discussed. However, if complete resection can-
not be achieved or if multifocal dysplasia is present, patients are 
advised to undergo colectomy.
 Historically, lesion categorization into sporadic adenoma or 
UC-associated dysplasia was made on the basis of the endoscopic, 
histological, and immunohistochemical analysis. As there is no 
clearcut distinction between such lesions, the UC-associated dys-
plasia/adenoma categorization represented in this study refl ects 
the  clinical consensus made at the time of diagnosis.
 Study protocol
 Inclusion and exclusion criteria .  All patients with a histological 
diagnosis of UC, with macroscopic and microscopic infl amma-
tion proximal to splenic fl exure, were included. Index colonosco-
py was defi ned as the fi rst surveillance colonoscopy performed at 
our institution subsequent to the patient entering the surveillance 
program, occurring 8 to 10 years from onset of UC symptoms.
 Patients were excluded from this study if they had the disease 
for <8 years, except for those considered to be at signifi cant risk 
of CRC who began surveillance before 8 years from disease onset 
(e.g., patients with concomitant primary sclerosing cholangitis). 
Patients were excluded if they had a diagnosis of CRC before in-
dex colonoscopy or if they were referred from other centers with 
a diagnosis of dysplasia.
 Data collection .  Th is study was approved by the Brent Research 
Ethics Committee and R&D Department at North West London 
Hospitals NHS Trust (reference number: 09/H0717/4). Patient 
data were obtained from the prospective UC surveillance data-
base, clinical notes, endoscopy and histology reports, as well as 
surgical records. If a patient had died, death certifi cate information 
was reviewed. Data on the date, grade, and site of all episodes of 
neoplasia (sporadic adenoma, UC-associated dysplasia, or CRC) 
were collected. Each dysplasia was graded according to the 1983 
Infl ammatory Bowel Disease Dysplasia Morphology Study Group 
Classifi cation of Dysplasia ( 17 ). Episodes of dysplasia occurring 
before 1983 had been previously reclassifi ed according to these 
standardized criteria ( 11 ). All data were collected into a custom 
Microsoft  Access 2010 database (Microsoft , Redmond, WA).
 End point categorization .  Primary end points: the primary study 
end points were the earliest occurring of the following: (i) death, 
(ii) colectomy, (iii) withdrawal from the surveillance program, or 
(iv) censor date (1 January 2013).
 Secondary end point (postsurveillance follow-up): to ensure 
identifi cation of all cancer cases in patients who had left  the sur-
veillance program, data were obtained from the UK National 
Cancer Registry. Secondary end points were as follows: (i) CRC 
diagnosed since leaving surveillance and (ii) no documented diag-
nosis of CRC since leaving surveillance.
 Categorization of CRC detection modalities .  Each CRC case was 
categorized into two groups based on how the cancer diagnosis 
was made, defi ned as follows.
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 1 .  Per-Protocol Surveillance (PPS) CRC: cancer detected 
in patients who had good compliance to the surveillance 
program, where they had a regular surveillance with recom-
mended interval. Th ese are subdivided into two groups. 
 1 .  Surveillance CRC: cancer detected in a planned surveil-
lance procedure or colectomy performed for dysplasia, in 
otherwise asymptomatic patients. 
 2 .  Interval CRC: cancer detected in symptom-driven inves-
tigations or surgery before the next scheduled surveil-
lance procedure. 
 2 .  Non-Per-Protocol Surveillance (NPPS) CRC: cancer detected 
at least 6 months aft er the date of originally planned surveil-
lance procedures. Th ese are subdivided into two groups. 
 1 .  Defaulted: cancer detected in poorly compliant patients 
who failed to attend scheduled surveillance before cancer 
diagnosis. 
 2 .  Non-defaulted: cancer detected aft er the patients were 
transferred to another hospital for their care or whose 
surveillance was terminated because of their age or 
comorbidities. 
 Statistical analysis .  Th e data analysis was performed using the 
SPSS statistical soft ware (version 20, IBM, Armonk, NY). All 
continuous variables are reported as medians with interquartile 
range (IQR). Study end points were examined using time-to-
event analysis using Kaplan–Meier and Cox proportional hazard 
methods. A linear regression model was developed to determine 
time trends in CRC incidence. A  P value of <0.05 was considered 
statistically signifi cant.
 RESULTS
 Study population
 A total of 1,375 patients met the inclusion criteria (55.3% males, 
 n =760/1,375). Of these patients, 57 had the concomitant history 
of primary sclerosing cholangitis (4.1% of study population). 
Th e median age of UC onset was 30 years (IQR, 22–40 years). Th e 
cumulative follow-up duration from the index colonoscopy to 
the primary end point was 15,234 patient-years (median, 11 years 
per patient; IQR, 7–17 years).
 A total of 8,650 colonoscopies were performed during the 
study period (median, 5 per patient; IQR, 3–8), of which 1,098 
were chromoendoscopy. Excluding 100 patients who underwent 
chromoendoscopy in 2002 as a part of the research protocol 
conducted in our center ( 6 ), there has been a signifi cant 
increase in the proportion of chromoendoscopy (i.e., number of 
chromoendoscopy/total number of colonoscopy) performed per 
year over the past 10 years (linear regression,  R =0.98,  P <0.001; 
 Figure 1 ). Overall, a total of 583 patients had at least one or more 
chromoendoscopy performed between 2003 and 2012 (54.5% 
of 1,070 patients who were under surveillance between 2003 
and 2012).
 Th e mean colonoscopy interval in the fi rst decade of surveil-
lance (1973–1982) was 1.78 years and this remained unchanged 
for the second (1983–1992; 1.95 years), third (1993–2002; 1.89 
years), and fourth (2003–2012; 1.77 years) decades. Th ere were 
no documented perforations or deaths resulting from surveillance 
procedures.
 Study outcome
 Th e primary study outcome is shown in  Table 1 . As of 1 January 
2013, 851 patients were undergoing active surveillance. Second-
ary follow-up (post-surveillance follow-up) data were obtained 
for 255 patients who had left  the surveillance program for reasons 
other than colectomy or death, as shown in  Table 1 .
 Colorectal cancer
 Patient demographics .  CRC was detected in 72 patients 
( n =72/1,375, 5.2% of study population) who were undergoing 
surveillance (incidence rate (IR), 4.7 per 1,000 patient-years).
 Furthermore, an additional 16 patients ( n =16/1,375, 1.2%) 
developed CRC in a median of 7.5 years (IQR, 5–11.3 years) 
aft er leaving surveillance (IR, 1.1 per 1,000 patient-years). 
Eight of these 16 patients who developed cancer aft er leaving 
the surveillance program had defaulted the recommended sur-
veillance and were lost to follow-up until CRC diagnosis was 
made elsewhere. Another eight patients were transferred to 
another hospital, thereby terminating their surveillance at our 
institution.
 Of the 88 patients who were diagnosed with CRC, 54 were 
male ( n =54/88, 61.4%). Th e median duration of UC at the time 
of CRC diagnosis was 23.5 years (IQR, 16–30 years;  Figure 2a ). 
Th e median age at the time of CRC diagnosis was 55.5 years (IQR 
44–63 years;  Figure 2b ).
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 Figure 1 .  A linear regression plot showing the proportion of surveillance 
colonoscopies performed with chromoendoscopy (number of chromo-
endoscopy / total number of colonoscopy) from 2003 to 2012.
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 Within surveillance, the cumulative incidence of CRC was 0.1% 
in the fi rst decade since the UC symptom onset ( Figure 2a ), fol-
lowed by 2.9%, 6.7%, and 10.0% by second, third, and fourth dec-
ade, respectively. Aft er the fi rst decade of the disease, there was no 
signifi cant change in hazard rate of CRC with further increase in 
disease duration (χ 2 ;  P =0.67), and remained relatively constant at 
∼ 0.37% per year.
 Mode of CRC presentation and interval cancer .  Th e mode of 
CRC detection is shown in  Table 2 . Cancer was detected in 
scheduled surveillance procedures in 48 asymptomatic patients 
(i.e., surveillance CRC; IR, 3.2 per 1,000 patient-years) or be-
tween surveillance interval in 15 patients (i.e., interval CRC; IR, 
1.0 per 1,000 patient-years).
 Th e proportion of Dukes’ C or disseminated cancer was sig-
nifi cantly lower in the surveillance-detected group ( n =11/45, 
24.4%) compared with interval CRC group ( n =11/14, 78.6%; χ 2 , 
 P <0.001) or CRCs detected in patients who defaulted surveil-
lance before the cancer diagnosis ( n =7/13, 53.8%;  P =0.04).
 Th e proportion of Dukes’ C or disseminated cancer was lower 
in the PPS group compared with the NPPS group, but this was 
not statistically signifi cant ( n =22/59, 37.3% vs.  n =9/18, 50.0%; χ 2 , 
 P =0.34).
 Change in CRC incidence over time .  Linear regression showed 
a decreasing but nonsignifi cant change in the overall annual IR of 
CRC during the four decades of the surveillance program ( R =−0.24; 
 P =0.13). Similarly, there was no signifi cant change in the incidence 
of the proximal ( R =−0.25;  P =0.11) or distal ( R =0.03;  P =0.83) cancer.
 As the study performed in our center a decade ago showed a sig-
nifi cant reduction in incidence of CRC over time ( 1 ), we performed 
an additional analysis to compare the per-decade CRC IR over the 
past 40 years—i.e., fi rst (1973–1982; 790 patient-years), second 
(1983–1992; 2,251 patient-years), third (1993–2002; 4,602 patient-
years) and fourth (2003–2012; 7,591 patient-years) decades. Th is 
revealed that although the overall CRC IR had decreased over the 
fi rst three decades, there was a nonsignifi cant increase in CRC IR in 
the fourth decade (4.9 per 1,000 patient-years) compared with the 
third decade (3.7 per 1,000 patient-years; χ 2 ,  P =0.30;  Figure 3a ).
 Th e IR of Dukes’ A or B had also decreased over the fi rst three dec-
ades. However, this was followed by a signifi cant increase in the fourth 
decade (3.2 per 1,000 patient-years) compared with the third decade 
(1.3 per 1,000 patient-years; χ 2 ,  P =0.045). Contrastingly, the IR of 
Dukes’ C or disseminated cancer had steadily decreased over the past 
four decades (Pearson’s correlation, −0.99;  P =0.01;  Figure 3b ).
 Th ere was a non-signifi cant increase in the IR of Dukes’ A or 
B in patients whose CRC was detected during surveillance colo-
noscopy or at the time of colectomy performed for dysplasia in 
the fourth decade compared with the third decade (3.0 vs. 1.3 per 
1,000 patient-years;  P =0.06). Contrastingly, the IR of Dukes’ C or 
disseminated disease for this group of patients remained similar 
(1.1 vs. 1.1 per 1,000 patient-years;  P= 1.0).
 Th e IR of interval cancer per decade had reduced signifi cantly 
over the past four decades, from 2.5 per 1,000 patient years in 
the fi rst decade to 0.4 per 1,000 patient-years in the fourth dec-
ade ( Figure 4a ; Pearson’s correlation, −0.99;  P =0.007). In the past 
three decades, at least one in three PPS cancers was interval cancer: 
33.3% ( n =2/6; 1973–1982), 50.0% ( n =4/8; 1983–1992), and 37.5% 
( n =6/16; 1993–2002). However, this was reduced to 9.1% in the 
current decade ( n =3/33; 2003–2012; Fisher’s exact test between the 
past three decades vs. current decade,  P =0.007;  Figure 4b ).
 Th e IR of UC-associated dysplasia was signifi cantly increased 
in the fourth decade compared with the third decade (17.7 vs. 
11.7 per 1,000 patient-years; χ 2 ,  P =0.01). Th e largest change was 
observed in IR of LGD (11.3 vs. 6.3 per 1,000 patient-years; χ 2 , 
 P =0.006) with smaller non-signifi cant increase in IR of HGD (3.4 
vs. 3.0 per 1,000 patient-years;  P =0.72) and indefi nite for dysplasia 
(2.9 vs. 2.4 per 1,000 patient-years;  P =0.60). Th e IR of sporadic 
adenoma was similar between the two decades (5.3 vs. 6.9 per 
1,000 patient-years; χ 2 ,  P =0.24).
 Tumor locations and multifocality .  In relation to the splenic fl ex-
ure, 41 CRCs were distal ( n =41/72, 56.9% of all cancers exclud-
ing those detected in postsurveillance period) and 26 ( n =26/72, 
36.1%) were proximal. In three cases ( n =3/72, 4.2%), synchro-
nous tumors were found located in both segments. Th e primary 
site was not known for two patients ( n =2/72, 2.8%) with dissemi-
nated disease. Colectomy specimens were available for analysis 
in 64 cases. Of these, 24 ( n =24/64, 37.5%) revealed either multi-
 Table 1 .  Primary end point categorization 
 Primary study outcome for 1,375 patients  Numbers (% of 
study population) 
 Patients on surveillance as of 1 January 2013 ( n =851) 
 No dysplasia  764 (55.6) 
 Dysplasia  87 (6.3) 
  • Indefi nite dysplasia  11 
  • LGD  68 
  • HGD  7 
 CRC, awaiting surgery  1 
 Patients not on surveillance as of 1 January 2013 ( n =524) 
 Surgery  218 (15.9) 
  • For CRC: 22 had CRC in specimen  24 
  • For dysplasia: 31 had CRC in specimen  87 
  • For symptoms: 11 had CRC in specimen  103 
  Surgery elsewhere following CRC during 
surveillance 
 4 
 Died while under surveillance  51 (3.7) 
  • CRC without colectomy  3 
  • Unrelated  48 
 Other reason for leaving surveillance  255 (18.5) 
  • Age/comorbidities/defaulted/patient choice  150 
  • Transfer of care to another hospital  95 
  • Noncolorectal malignancy  10 
 CRC, colorectal cancer; HGD, high-grade dysplasia; LGD, low-grade dysplasia. 
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 Figure 2 .  Kaplan Meier plots and life tables showing cumulative risk of colorectal cancer (CRC) development. ( a ) Cumulative risk of CRC by duration of 
ulcerative colitis (UC). ( b ) Cumulative risk of CRC by age of patients.
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synchronous CRC or solitary CRC with spatially distinct dysplas-
tic lesion(s) elsewhere in the colon ( Table 3 ).
 Preceding dysplasia .  In all, 44 patients ( n =44/72, 61.1% of all can-
cers excluding those detected in post-surveillance) previously had 
neoplasia, of which 41 were UC-associated dysplasia and 3 were 
sporadic adenoma. Th e remaining 28 patients ( n =28/72, 38.9%) 
had neither sporadic adenoma nor UC-associated dysplasia de-
tected during surveillance.
 Survival following CRC diagnosis .  Ultimately, 37.5% of patients 
died from CRC (100% with disseminated disease, 47.8% with 
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 Table 2 .  Mode of colorectal cancer (CRC) detection and Dukes’ staging 
 Dukes’ stage  Surveillance detected 
(per-protocol surveillance) 
 Interval (per-protocol 
surveillance) 
 Defaulted (non-per-
protocol surveillance) 
 Nondefaulted (non-
per-protocol surveillance) 
 Total (%) 
 A  24  1  3  0  28 (31.8) 
 B  10  2  3  3  18 (20.4) 
 C  11  7  5  1  24 (27.2) 
 D  —  4  2  1  7 (8.1) 
 Unknown  3  1  4  3  11 (12.5) 
 Total (%)  48 (54.5)  15 (17.1)  17 (19.3)  8 (9.1)  88 (100) 
 Incidence rate (per 1,000 
patient-years) 
 3.2  1.0  1.1  0.5  5.8 
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survival rate was 92.3% for Dukes’ A, 86.2% for Dukes’ B, 68.9% 
for Dukes’ C, and 100% for disseminated cancer ( Figure 5a ). Th e 
10-year survival rate was 77.0% for Dukes’ A, 86.2% for Dukes’ B, 
and 51.7% for Dukes’ C. Th e overall survival rate was 72.0% and 
60.6% at 5 and 10 years, respectively.
 Th e overall survival rate was signifi cantly diff erent depending 
on the mode of CRC detection (log-rank test,  P =0.01;  Figure 5b ). 
Th e 5- and 10-year survival rate was 81.8% and 75.1% for PPS-
Surveillance detected CRC, 68.8% and 59.6% for NPPS CRC, and 
46.7% and 23.3% for PPS-Interval CRC, respectively.
 Surgery
 During their surveillance, 214 patients ( n =214/1,375, 15.6% of 
the study population) underwent colonic surgery. Th e combined 
cumulative incidence of colonic surgery or cancer diagnosis by 
UC disease duration was 1.9% at 10 years, 10.8% at 20 years, 
17.4% at 30 years, and 24.3% at 40 years. Th e combined cumula-
tive incidence of colonic surgery or cancer diagnosis by patient 
age was 1.4% at 30 years, 4.2% at 40 years, 7.5% at 50 years, and 
13.9% at 60 years.
Dukes’ C, 23.5% of Dukes’ B, and 17.2% of Dukes’ A cancer). Th e 
overall survival rate was signifi cantly diff erent depending on the 
Dukes’ stage of the cancer (log-rank test,  P <0.001). Th e 5-year 
 Table 3 .  Dukes’ staging and multifocality of colorectal cancer (CRC) cases (excluding CRC cases detected in postsurveillance period) 
 Dukes’ stage  Solitary CRC  Solitary CRC with spatially distinct dysplasia(s)  Synchronous CRC  Unknown  Total (%) 
 A  16  7  4  —  27 (37.5) 
 B  7  5  1  —  13 (18.1) 
 C  16  2  4  —  22 (30.5) 
 D  —  —  —  4 a  4 (5.6) 
 Unclassifi able  1 b  —  —  1 c  2 (2.8) 
 Operation elsewhere  —  —  1 d  3  4 (5.6) 
 Total (%)  40 (55.6)  14 (19.4)  10 (13.9)  8 (11.1)  72 (100) 
 a Two patients did not have surgery and hence tumor locations were unknown. Full details on neoplasia locations were not available for the other two patients who had 
emergency operation elsewhere. 
 b Staging was not possible because of preoperative radiotherapy. 
 c Patient currently waiting for colectomy. 
 d Patient had multisynchronous CRCs in rectum, transverse colon, and hepatic fl exure with widespread dysplasias detected during surveillance colonoscopy, and then had 
operation elsewhere. 
1.0
a b
0.8
O
ve
ra
ll s
ur
viv
al
0.6
0.4
0.2
0.0
Years since CRC diagnosis
Dukes’ stage Mode of CRC
detection
PPS CRC: surveillance
NPPS CRC
PPS CRC: interval
A
Log-rank, P<0.001 Log-rank, P<0.01
B
C
Disseminated
0 5 10 15 20 25
1.0
0.8
O
ve
ra
ll s
ur
viv
al
0.6
0.4
0.2
0.0
Years since CRC diagnosis
0 5 10 15 20 25
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 Linear regression revealed a signifi cant decrease in the incidence 
of colectomy for any indication ( R =−0.37;  P =0.02). Particularly, the 
incidence of colectomy performed for dysplasia showed steeper 
decrease ( R 2 =−0.22;  P =0.003) over time ( Figure 6 ). Overall, when 
an indication for surgery was HGD, 48.6% ( n =18/37) of the patients 
had CRC in surgical specimen ( Table 4 ). For those who had colec-
tomy for LGD, CRC was found in 25.5% ( n =12/47) of cases. Th ere 
was no time trend in proportion of CRC detected in colectomy 
specimen on performing colectomy for LGD (Pearson’s correlation, 
−0.68;  P =0.32) or HGD (Pearson’s correlation, 0.42;  P= 0.59).
 Neoplasia (sporadic adenoma, UC-associated dysplasia, or 
cancer)
 Overall, 325 patients ( n =325/1,375, 23.6% of study population) 
had a total of 635 episodes of neoplasia during the study period 
(IR, 41.7 per 1,000 patient-years). Th e median age of neopla-
sia diagnosis between 1993 and 2012 was 60 years (IQR, 49–68 
years), and this was signifi cantly older than in the previous two 
decades (1973–1992; 49 years; IQR, 38–57 years; Mann–Whitney 
 U ,  P <0.001). Th ere was no signifi cant change in the median age 
of diagnosis between the recent two decades (i.e., 2003–2012 vs. 
1993–2002;  P =0.7).
 Th e cumulative incidence of neoplasia by UC duration was 
4.1% at 10 years, 14.1% at 20 years, 28% at 30 years, and 38.9% 
at 40 years ( Figure 7a ). Th e average hazard rate of develop-
ing neoplasia per year in the fi rst 40 years of the UC was 1.0% 
(s.e., 0.056%).
 Chromoendoscopy .  We compared the lesion detection rate 
(defi ned as number of procedures in which one or more neopla-
sia was detected divided by total number of procedures) between 
the standard white-light colonoscopy and chromoendoscopy 
performed from 2002 to 2012 ( Table 5 ). Overall, the neoplasia 
detection rate was twofold higher in the chromoendoscopy group 
( n =92/1,098, 8.4%) compared with the white-light colonoscopy 
group ( n =175/4,373, 4.0%; χ 2 ,  P <0.001).
 Among the patients who were on surveillance between 2002 
and 2012, the IR of CRC in patients who had at least one or more 
chromoendoscopies performed (median, 1 per patient; IQR, 1–2) 
was signifi cantly lower (2.2 per 1,000 patient-years) than in those 
who had never had chromoendoscopy (4.6 per 1,000 patient-years; 
χ 2 ,  P =0.02).
 Since 2003, 13 cases of CRC were detected at colonoscopy 
following a “negative for dysplasia” colonoscopy performed a 
median of 23 months (IQR, 13–25 months) previously. Assum-
ing that CRC was missed at the previous procedure, the postcolo-
noscopy colorectal cancer rate (i.e., PCCRC or miss rate) was 1.2 
per 1,000 patient-years (2/1,726 patient-years) for chromoendo-
scopy and 1.8 per 1,000 patient-years (11/6,176 patient-years) for 
white-light endoscopy, although the diff erence was not statisti-
cally signifi cant ( P =0.6).
 Sporadic adenoma .  A total of 85 patients ( n =85/1,375, 6.2% of 
the study population) had a total of 143 episodes of sporadic ad-
enoma (IR, 9.4 per 1,000 patient-years). Neoplastic progression 
was studied in 76 patients excluding patients who have not had a 
follow-up colonoscopy ( n =9).
 Th irty-seven patients ( n =37/76, 48.7%) had adenoma detected 
outside the diseased segments. During 293 patient-years of follow-up 
(median, 7.5 years per patient; IQR, 4–11 years), 4 patients ( n =4/37, 
10.8%; IR, 13.7 per 1,000 patient-years) developed LGD and addi-
tional 2 patients had developed Dukes’ A CRC ( n =2/37, 5.4%; 
incidence rate, 6.8 per 1,000 patient-years): one within a severely dys-
plastic tubulovillous adenoma that was not endoscopically resectable, 
and the other at 2.5 years aft er having an adenoma resected from a 
diff erent colonic segment.
 Th e remaining 39 patients ( n =39/76, 51.3%) had their 
adenoma detected within the diseased segment. During 369 
patient-years of follow-up (median, 7 years per patient; IQR, 
4–11 years), 5 had developed LGD ( n =5/39, 12.8%; IR 13.6 per 
1,000 patient-years) and 1 had progressed to Dukes’ A CRC 
( n =1/39, 2.6%; IR, 2.7 per 1,000 patient-years) within an ade-
noma 5 years aft er having an adenoma resected from the same 
colonic segment.
 Th ere was no diff erence in CRC risk between adenoma detected 
within or outside the diseased segment of colon (χ 2 ,  P =0.44).
 Table 4 .  Indication for surgery and maximal neoplasia found in surgical specimen 
 Indication for surgery (no. of patients)  Findings in surgical specimen 
  No dysplasia  Adenoma only  Indefi nite for dysplasia  LGD  HGD  CRC (%) 
 Symptoms (103)  81  4  0  6  1  11 (10.7) 
 Adenoma (1)  0  1  0  0  0  0 (0) 
 Indefi nite for dysplasia (2)  1  0  0  0  0  1 (50.0) 
 LGD (47)  12  0  1  16  6  12 (25.5) 
 HGD (37)  0  0  2  5  12  18 (48.6) 
 CRC (24)  1  0  0  1  0  22 (91.7) 
 Total (214)  94  5  3  30  18  64 (100) 
 CRC, colorectal cancer; HGD, high-grade dysplasia; LGD, low-grade dysplasia. 
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 Figure 7 .  Risk of developing neoplasia over time. ( a ) Kaplan–Meier plot and a life table showing the risk of developing any neoplasia (i.e. adenoma, 
dysplasia, or colorectal cancer (CRC)) by duration of UC. ( b ) Kaplan–Meier plot and a life table showing cumulative incidence of CRC for each type of 
neoplasia grade. HGD, high-grade dysplasia; LGD, low-grade dysplasia.
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 Indefi nite for dysplasia .  Fift y-one patients ( n =51/1,375, 3.7% of 
study population) had 64 episodes of indefi nite for dysplasia (IR, 
4.2 per 1,000 patient-years). Neoplastic progression was studied 
in 49 patients over 411 patient-years of follow-up (median, 4.6 
years per patient; IQR, 2.7–13.1 years), excluding 2 patients who 
had no follow-up colonoscopy. Overall, 25 patients ( n =25/49, 
51.0%; IR, 60.8 per 1,000 patient-years) progressed to LGD, HGD, 
or CRC during the study period ( Supplementary Figure S1A 
online). Furthermore, 12 of these patients ( n =12/49, 24.5) had 
eventually progressed to CRC (IR, 29.2 per 1,000 patient-years). 
Six patients ( n =6/49, 12%; IR, 14.6 per 1,000 patient-years) pro-
gressed to HGD (3 patients) or CRC (3 patients) without an epi-
sode of LGD in between.
 Low-grade dysplasia .  A total of 156 patients ( n =156/1,375, 11.3% 
of study population) developed 280 episodes of LGD (IR of 18.4 
per 1,000 patient-years). All patients were subsequently followed 
for 658 patient-years ( Supplementary Figure S1B ), except for 11 
patients who did not have a follow-up colonoscopy ( n =7) or their 
LGD was incidentally found in the surgical specimen aft er they 
had undergone colectomy for UC symptoms ( n =4).
 Th irty-two patients ( n =32/145, 22.1%) with LGD underwent 
immediate colectomy, 9 of whom had CRC in the surgical speci-
men ( n =9/32, 28.1% of those who underwent immediate colec-
tomy). In 6 of these patients, cancer was found in the region where 
LGD was previously detected ( n =6/9, 66.7%).
 A total of 113 patients ( n =113/145, 77.9% of patients with LGD) 
initially remained in the surveillance program. During the median 
follow-up of 4.2 years (IQR, 2.4–7.2 years), 18 developed CRC 
( n =18/113, 15.9% of LGD population who initially remained in 
surveillance). Overall, 47 out of 145 patients with LGD (32.4%) had 
progressed to more advanced neoplasia (IR, 71.4 per 1,000 patient-
years); i.e., HGD ( n =20/145, 13.8%; IR, 30.4 per 1,000 patient-
years) or CRC ( n =27/145, 18.6%; IR, 41.0 per 1,000 patient-years).
 High-grade dysplasia .  Forty-eight patients developed a total of 
76 episodes of HGD ( n =48/1,375, 3.5%; IR, 5.0 per 1,000 patient-
years) and were subsequently followed for a cumulative total of 
86.8 patient-years ( Supplementary Figure S1C ). Twenty-four 
patients with HGD ( n =24/48, 50.0%) had previously had a 
diagnosis of LGD.
 Twenty-nine patients with HGD underwent immediate colec-
tomy, 16 of whom had CRC in surgical specimen ( n =16/29, 55.2%). 
In nine of these patients, CRC was found in the region where HGD 
was previously detected ( n =9/16, 56.3%).
 Nineteen patients initially remained in the surveillance pro-
gram. Over a median follow-up duration of 2.8 years (IQR, 1.6–6.0 
years), recurrent dysplasia was detected in 16 patients, and 4 of 
these patients ( n =4/19, 21.1% of those who initially remained in 
surveillance) had eventually progressed to CRC. Overall, 20 out 
of 48 HGD patients (41.7%) had progressed to CRC (IR, 230.4 per 
1,000 patient-years).
 Rate of progression to CRC by neoplastic grade (sporadic adeno-
ma, indefi nite for dysplasia, LGD, and HGD) .  Th e Kaplan–Meier 
plot and a table showing cumulative incidence of CRC for each 
type of neoplasia grade is shown in  Figure 5b . Th ere was no sig-
nifi cant diff erence in the risk of CRC between indefi nite and LGD 
group (log-rank test,  P =0.79) or between sporadic adenoma and 
no dysplasia group ( P =0.14).
 Th e hazard ratio of developing CRC for each type of neoplasia 
compared with patients with no dysplasia was: sporadic adenoma, 
0.50 (95% confi dence interval, 0.2–1.6;  P =0.3), indefi nite for dys-
plasia, 6.1 (95% confi dence interval, 1.7–21.5;  P =0.005), LGD, 7.8 
(95% confi dence interval, 2.4–25.7;  P <0.001), and HGD, 33.1 (95% 
confi dence interval, 9.7–112.9;  P <0.001).
 Th e annual hazard rate for developing CRC in the fi rst 5 years 
from the time of initial neoplasia diagnosis was as follows: spo-
radic adenoma (0.64%; s.e., 0.005), indefi nite for dysplasia (5.5%; 
s.e., 0.017), LGD (4.8%; s.e., 0.010), and HGD (14.8%; s.e., 0.031).
 DISCUSSION
 Th is study provides an overview of the largest and longest-run-
ning UC surveillance program in the world over its 42-year his-
tory, revealing an important recent trend in CRC risk, tumor 
characteristics, and progression of dysplasia.
 Reduction in risks of advanced cancer and interval cancer
 Our data show that the advanced cancer IR has decreased consist-
ently over the past four decades, potentially indicating that the 
effi  cacy of colonoscopic surveillance in early detection of CRC 
 Table 5 .  Comparison of the lesion detection rate between white-light endoscopy (WLE) and chromoendoscopy (CE) from 2002 to 2012 
 Type  Number detected in WLE:  n =4,373 
(detection rate %) 
 Number detected in CE:  n =1,098 
(detection rate %) 
 Superior 
technique 
 P  value 
 Adenoma  28 (0.6)  16 (1.5)  CE  0.007 
 Indefi nite for dysplasia  24 (0.6)  16 (1.5)  CE  0.002 
 LGD  99 (2.3)  48 (4.4)  CE  <0.001 
 HGD  24 (0.6)  12 (1.1)  CE  0.05 
 All neoplasias (excl. CRC)  175 (4.0)  92 (8.4)  CE  <0.001 
 CRC, colorectal cancer; HGD, high-grade dysplasia; LGD, low-grade dysplasia. 
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 Increasing IR of dysplasia: overdiagnosis?
 Th e fact that no reduction in CRC risk was seen despite the intro-
duction of advanced endoscopy and the concomitant increase in 
the neoplasia detection rate in recent years raises the possibil-
ity of  overdiagnosis : that advanced endoscopy leads to the detec-
tion of proportionally more indolent lesions. If this were true, 
one would expect that the rate of progression from dysplasia to 
CRC would be lower in the chromoendoscopy era as many of the 
“extra” lesions detected will not progress to CRC.
 We tested for this possibility using the cohort of patients who 
were diagnosed with LGD in the current decade (90 patients 
followed up for 264 patient-years) and the past decade (29 
patients followed up for 153 patient-years), as the increase in 
IR of UC-associated dysplasia had mainly resulted from the LGD 
group. Th is revealed that the rate of progression from LGD to 
CRC was in fact similar (45.5 vs. 52.3 per 1,000 patient-years 
in the current and past decades;  P =0.96), making overdiagno-
sis an unlikely possibility. In other words, these “extra” dysplas-
tic lesions that are detected in the current decade are likely to 
have equivalent risk of progression of CRC compared with those 
detected in the previous decade.
 Overall cancer risk by disease duration remains low
 Consistent with our previous study ( 1 ), the overall risk of CRC 
by disease duration remained low (only 10.0% of patients deve-
loped cancer at 40 years of disease duration). Th e CRC risk also 
remained relatively constant aft er 10 years of the disease, and this 
is in agreement with the recent Danish nationwide cohort study 
( 2 ), suggesting that intensifying the surveillance interval with 
increasing duration of the UC is not necessary.
 Frequent synchronous lesions
 Th e frequency of synchronous CRC was high (15.6%), comparable 
to previous reports ( 18,19 ). However, none of these studies reported 
multifocal dysplasia occurring with unifocal cancers: our data indi-
cate that a signifi cant proportion of patients with CRC also have 
synchronous dysplasia elsewhere in the colon (37.5%). Evidence 
suggests that infl ammatory bowel disease-associated cancers arise 
from a larger fi eld of colorectal mucosa that is “preconditioned” 
with a mutational burden that confers an increased propensity for 
further neoplastic progression, a phenomenon known as “fi eld can-
cerization” ( 20–22 ). Th e high frequency of multifocal cancer/dys-
plasia reported in our cohort likely refl ects that fi eld cancerization 
is a common phenomenon in patients with UC.
 Neoplastic progression of sporadic adenoma and dysplasia
 In accordance with other previous studies ( 23,24 ), the rate of CRC 
in patients undergoing immediate colectomy for HGD was high 
(50%). Furthermore, 84% of those who remained in surveillance 
had a recurrence of HGD or progression to CRC aft er a median of 
1.13 years (IQR, 1–1.5 years). In this context, given the high risk 
of recurrence of HGD and progression to cancer, patients with 
HGD would likely benefi t from an early colectomy.
 Both indefi nite for dysplasia and LGD had a moderate risk of 
progression to CRC and the risks were similar to each other. It 
may have improved over time. A reasonably good prognosis of 
early CRC compared with the advanced CRC shown in our study 
highlights the importance of early detection of CRC in reducing 
the cancer mortality.
 Th e risk of interval cancer, although once common, is rapidly 
decreasing. Th is is a particularly reassuring fi nding as interval 
cancers tended to be advanced and hence associated with poor 
prognosis (78.6% of interval cancers were Dukes’ C or dissemi-
nated disease), and consequently the reduction in advanced cancer 
risk is likely to have resulted from the decreasing IR of interval 
cancers. Th e steepest decrease in its risk was seen in the current 
decade, suggesting that the use of chromoendoscopy, which was 
more eff ective in lesion detection, may have been a signifi cant con-
tributory factor in minimizing the risk of missing prior dysplastic 
lesions at colonoscopy. Indeed, the IR of HGD or CRC detected 
in patients with no previous indefi nite for dysplasia or LGD was 
signifi cantly reduced in the current decade (2.1 per 1,000 patient-
years) compared with the past decade (4.6 per 1,000 patient-years; 
χ 2 ,  P =0.02), indicating that the negative predictive value of the 
surveillance colonoscopy may have improved signifi cantly.
 Interestingly, patients who had chromoendoscopy had a lower 
risk of developing CRC compared with those who never had the 
procedure. Moreover, the postcolonoscopy colorectal cancer rate 
was lower following chromoendoscopy compared with white-light 
endoscopy, although this was not statistically signifi cant. Although 
these initial data support the use of chromoendoscopy, it should 
be emphasized that the prospective multicenter trials over long 
period of follow-up is required to accurately assess the effi  cacy of 
chromoendoscopy as it is equally possible that other external fac-
tors, such as better medical treatments, may have also had a signifi -
cant role in reduction of these risks.
 Decreasing colectomy for dysplasia and increase in early cancer 
incidence
 Despite falling IR of advanced cancer, an increase in the IR of 
early cancers (Dukes’ A and B) meant that there was no sig-
nifi cant diff erence in the  overall IR CRC in the current decade 
compared with the past decade. Furthermore, there was no sig-
nifi cant change in the proportion of CRCs detected at colectomy 
for dysplasia over time.
 A likely explanation for this trend is the recent signifi cant ten-
dency to manage dysplasia endoscopically instead of by colec-
tomy: indeed, the colectomy rate has fallen despite a rise in the 
incidence of dysplasia. Th us, it is possible that some of these 
patients who were managed endoscopically have subsequently 
progressed to CRC. As increasing number of patients are retain-
ing their colon for longer, one can argue that this may be an 
acceptable outcome as it may indicate that patients are being 
off ered delayed but timely colectomy (e.g., before progressing to 
advanced CRC). Furthermore, we observed an increase in patient 
age at dysplasia diagnosis that is perhaps the result of reduction in 
the risk of competing interests in recent years (such as heart dis-
ease), and coupled with the relatively good prognosis associated 
with early CRC, these data suggest that prophylactic colectomy 
is a less favored and acceptable option for dysplasia management.
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is well documented that grading of dysplasia is diffi  cult, and the 
inter-observer agreement in grading dysplasia among pathologists 
is poor, particularly for the indefi nite and LGD categories ( 13,14 ). 
Our data demonstrate that a diagnosis of LGD vs. indefi nite for 
dysplasia does not predict etiological diff erences in disease pro-
gression as suggested by other studies ( 25–27 ). Th ese fi ndings 
suggest that diff erential patient management decisions should not 
be made solely on the basis of an indefi nite for dysplasia vs. LGD 
diagnosis. Sporadic adenomas did not confer an additional CRC 
risk, and their risk was no diff erent to those without any neopla-
sia. Th is indicates that these lesions can be appropriately managed 
endoscopically without colectomy.
 Study limitations
 Our study has several limitations. First, this study was con-
ducted on a population at the tertiary referral center with higher 
proportion of patients with more severe or complex disease. 
Th is has a potential impact on generalizability of our results. 
For example, although our fi ndings refl ect CRC risk in extensive 
UC patients, a signifi cant proportion of patients will have left -
sided disease or proctitis only in general populations that may 
decrease the estimate of overall CRC risk. Second, the number of 
CRC cases was relatively small in our study, particularly for the 
time-trend analysis. Hence, it is possible that some observations 
were over- or underinterpreted because of relatively small num-
ber of cancer cases. Our fi ndings thus should be confi rmed in a 
population-based study before further conclusion can be made.
 Conclusions
 In conclusion, our data provide an overview of dysplasia/
CRC surveillance in UC over its 40-year history. Th e advent of 
chromo endoscopy in recent years has increased the rate of dys-
plasia detection. Th is has not led to the reduction in overall CRC 
risk, but has allowed the early identifi cation of high-risk patients 
and played an important role in reducing the risk of advanced 
and interval cancer. Th e colectomy rate for dysplasia has signifi -
cantly reduced over the past four decades with continued reduc-
tion in advanced cancer risk, but perhaps at the cost of a rise 
in early cancer incidence. However, given the good postsurgical 
outcome of early cancers, patients may be able to retain their 
colon despite a dysplasia diagnosis, although they should be 
fully informed of the risks and benefi ts associated with under-
going endoscopic or surgical management of dysplasia. Finally, 
patients with  any grade of dysplasia should be regarded as a sig-
nifi cant risk, and given the frequency of multi focal neoplasia, 
these patients require careful inspection of the entire colon with 
advanced techniques to ensure lesions are not missed.
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE
 ✓  Patients with long-standing ulcerative colitis (UC) have 
an increased risk of developing colorectal cancer (CRC), 
although the recent literature suggests that this risk might 
be decreasing. 
 ✓  However, it is unknown how emergence of new endoscopic 
techniques such as chromoendoscopy in recent years may 
have affected the incidence rates of CRC and dysplasia. 
 ✓  Furthermore, the risk of interval cancer and prevalence 
of multifocal neoplasia occurring in these patients are 
unknown. 
 ✓  The risk of CRC associated with each grade of dysplasia, 
especially “indefi nite for dysplasia” remains unclear. 
 WHAT IS NEW HERE
 ✓  The incidence rate of UC-associated dysplasia has in-
creased by 1.5-fold in the current decade (2003–2012) 
compared with the past decade (1993–2002), attributable 
to increased use of chromoendoscopy that was twofold 
more effective in detecting adenoma or dysplasia com-
pared with white-light endoscopy. 
 ✓  Despite a signifi cant decrease in incidence of colectomy 
performed for dysplasia over time, the incidence rate of 
Dukes’ C or disseminated cancer and interval cancer has 
decreased. However, there was a 2.5-fold increase in 
the incidence rate of Dukes’ A or B cancer in the recent 
decade compared with the past decade. Reassuringly, the 
10-year postsurgical survival rate was high for Dukes’ A or 
B cancers (79.6%). 
 ✓  Multifocal neoplasia is a common phenomenon, with 
approximately one in three CRCs (37.5%) having either 
a spatially distinct cancer or dysplasia in the colectomy 
specimen. 
 ✓  The risk of CRC associated with “indefi nite for dysplasia” 
or low-grade dysplasia was similar, with the cumulative 
incidence of CRC exceeding 20% within 5 years since the 
initial dysplasia diagnosis. 
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